Try our mobile app

Published: 2022-07-13 21:50:31 ET
<<<  go to RDY company page
EX-99.2 2 drr0410_ex99-2.htm EXHIBIT 99.2

 

Exhibit 99.2

 

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,
India.

CIN : L85195TG1984PLC004507  

 

Tel     : +91 40 4900 2900

Fax     : +91 40 4900 2999

Email : mail@drreddys.com

www.drreddys.com

 

July 13, 2022

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

 

Dear Sirs,

 

Sub: Earnings Call Notification

 

Please find enclosed a notification titled “Dr. Reddy's to release Q1 FY 23 results on July 28th, 2022 Earnings call slated for July 28th @ 6:30 PM IST / 9:00 AM EDT”

 

This is for your information.

 

Thanking you.

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

 

/s/ K Randhir Singh  
K Randhir Singh  

Company Secretary & Compliance Officer

 

Encl: As above

 

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

NSE IFSC Ltd.

 

  

 

 

 

  CONTACT

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500034. Telangana, India.

Investor relationS Media relationS

AMIT AGARWAL

amita@drreddys.com

USHA IYER

ushaiyer@drreddys.com

 

Dr. Reddy's to release Q1 FY 23 results on July 28th, 2022

Earnings call slated for July 28th @ 6:30 PM IST / 9:00 AM EDT

 

Hyderabad, India, July 13th, 2022

 

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the first quarter ended June 30th, 2022 on Thursday, July 28th, 2022 after the Board Meeting.

 

Summary of Events

 

Event   Date and Time   Medium
Release of financial results   July 28th, after the Board Meeting   Stock Exchange, Media, Company website, Business wire, Email
Press meet presentation   Will be available on the Company’s website   Company’s website www.drreddys.com
Earnings Call   July 28th, 6:30 PM IST / 9:00 AM EDT  

Hosted by the Company

(Details below)

Playback of Earnings Call   After the earnings call till August 3rd, 2022   Details below
Transcript of the Earnings call   Will be available on the Company’s website   Company’s website www.drreddys.com

 

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

 

Play Back

The play back will be available after the earnings call, till August 3rd, 2022. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is 96436.

 

 

 

  

 

 

Conference Joining Information

 

Option 1: Express Join with DiamondPass™

 

Pre-register with the below link and join without waiting for the operator.

 

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=3962534&linkSecurityString=119134f0e6

 

Option 2: Join through below Dial-In Numbers

Universal Access Number:

 

+91 22 6280 1219

+91 22 7115 8120

International Toll Free Number:

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

 

 

 

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

 

 

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

 

 

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.”

 

The company assumes no obligation to update any information contained herein.